ClinicalTrials.gov
ClinicalTrials.gov Menu

Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01626248
Recruitment Status : Completed
First Posted : June 22, 2012
Last Update Posted : June 14, 2013
Sponsor:
Collaborators:
Biogen
Elan Pharmaceuticals
Information provided by (Responsible Party):
John F. Foley, MD, Rocky Mountain MS Research Group, LLC